Markets:

Overview

News

Currencies

International

Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

38.37 -0.27 (-0.70%)

Streaming Delayed Price Updated: 10:32 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023

January 18, 2023

From Royalty Pharma plc

Via GlobeNewswire

Ominous Death Cross Forms On Royalty Pharma's Chart ↗

January 10, 2023

Via Benzinga

Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference

January 09, 2023

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness

January 09, 2023

From Royalty Pharma plc

Via GlobeNewswire

Looking Into Royalty Pharma's Return On Capital Employed ↗

December 06, 2022

Via Benzinga

Expert Ratings for Royalty Pharma ↗

August 08, 2022

Within the last quarter, Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings:

Via Benzinga

Royalty Pharma: Q2 Earnings Insights ↗

August 04, 2022

Royalty Pharma (NASDAQ:RPRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Royalty Pharma Announces Dividend Increase

January 09, 2023

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9

January 04, 2023

From Royalty Pharma plc

Via GlobeNewswire

6 Stocks Warren Buffett Completely Exited in 2022 ↗

December 17, 2022

Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of its holdings as it repositioned its portfolio.

Via The Motley Fool

Royalty Pharma Announces Expansion of Senior Leadership Team

December 15, 2022

From Royalty Pharma plc

Via GlobeNewswire

Expert Ratings for Royalty Pharma ↗

June 14, 2022

Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings within the last quarter:

Via Benzinga

Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference

November 28, 2022

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones

November 09, 2022

From Royalty Pharma plc

Via GlobeNewswire

Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones

November 09, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Royalty Pharma Reports Third Quarter 2022 Results

November 08, 2022

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma to Announce Third Quarter 2022 Financial Results on November 8, 2022

October 18, 2022

From Royalty Pharma plc

Via GlobeNewswire

If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position ↗

October 18, 2022

There may be more trouble on the horizon for these stocks than most investors are seeing right now.

Via The Motley Fool

Royalty Pharma Declares Fourth Quarter 2022 Dividend

October 17, 2022

From Royalty Pharma plc

Via GlobeNewswire

Jim Cramer Likes This Biotechnology Stock: 'It's Not Big, But It's Not Bad' ↗

October 14, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Royalty Pharma plc (NASDAQ: RPRX) and will stick with it. "It’s not big, but it’s not bad," he added.

Via Benzinga

Royalty Pharma Announces Expansion of Leadership Team

October 12, 2022

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Announces R&D Funding Collaboration With Merck

October 12, 2022

Novel collaboration structure supports pipeline innovation

From Royalty Pharma plc

Via GlobeNewswire

Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings ↗

September 19, 2022

Via Benzinga

Royalty Pharma's Return On Capital Employed Insights ↗

August 22, 2022

Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q2 earnings of $491.60 million, an increase from Q1 of 283.81%. Sales dropped to $535.96 million, a 4.63% decrease between quarters.

Via Benzinga

Warren Buffett's Berkshire Takes Another Bite Of Apple, Boosts Energy Holdings, Cashes Out Of Verizon: What 13F Filing Reveals ↗

August 16, 2022

Warren Buffett-owned Berkshire Hathaway, Inc.’s (NYSE: BRK-A) (NYSE: BRK-B) portfolio saw some noteworthy and a few other nominal changes in the second quarter, according to the company's 13F filing.

Via Benzinga

Jim Cramer Shares His Takes On First Solar, Royalty Pharma And More ↗

August 11, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Royalty Pharma PLC (NASDAQ: RPRX) is going higher. "Hold on to it."

Via Benzinga

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗

July 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests ↗

July 13, 2022

Via Benzinga

Warren Buffett Stocks: Royalty Pharma plc ↗

July 08, 2022

As of March 31st, 2022, Buffett’s Berkshire Hathaway owned about 1.5 million shares of Royalty Pharma plc for a market value of $58.3 million. Let's analyze the healthcare company in greater detail.

Via Talk Markets

This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation' ↗

June 30, 2022

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.